Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the Look AHEAD study.

Journal: Lancet regional health. Americas
Published Date: Nov 8, 2021

Abstract

BACKGROUND: Among patients with type 2 diabetes, minority racial/ethnic groups have a higher burden of cardiovascular disease, chronic kidney disease, and hypoglycaemia. These groups may especially benefit from newer diabetes medication classes, but high cost may limit access. We examined the association of race/ethnicity with the initiation of newer diabetes medications (GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors).

Authors

  • Ahmed Elhussein
    Department of Biomedical Informatics, Columbia University, New York Genome Center, New York, NY, USA.
  • Andrea Anderson
    Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, USA.
  • Michael P Bancks
    Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA.
  • Mace Coday
    Department of Preventive Medicine, The University of Tennessee Health Science Center, Memphis, TN, USA.
  • William C Knowler
    National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ, USA.
  • Anne Peters
    Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Elizabeth M Vaughan
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Nisa M Maruthur
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Jeanne M Clark
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Scott Pilla
    Department of Medicine, Division of General Internal Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals